Pozelimab + Cemdisiran ( DrugBank: Pozelimab, Cemdisiran )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 11 | 重症筋無力症 | 1 |
11. 重症筋無力症
臨床試験数 : 332 / 薬物数 : 234 - (DrugBank : 81) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05070858 (ClinicalTrials.gov) | December 14, 2021 | 27/9/2021 | A Study to Examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Symptomatic Generalized Myasthenia Gravis | Generalized Myasthenia Gravis | Drug: Pozelimab + Cemdisiran;Drug: Cemdisiran;Other: Placebo;Drug: Pozelimab | Regeneron Pharmaceuticals | NULL | Recruiting | 18 Years | N/A | All | 235 | Phase 3 | United States;Australia;Belgium;Canada;Czechia;Denmark;France;Italy;Japan;Korea, Republic of;Poland;Spain;Taiwan;Turkey;United Kingdom |